Phase II Trial of RAD001 in Refractory Colorectal Cancer
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Colorectal Cancer
DRUG: RAD001
Study is completed and closed.